On July 6, 2016 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) reported that the Company has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology (Press release, Evotec, JUL 6, 2016, View Source [SID:1234513728]). Schedule your 30 min Free 1stOncology Demo! Under the terms of this research tool licence, Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, especially for the development of research tools and in target identification, and to further strengthen its post phenotypical screening target deconvolution platform.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With this agreement, Evotec obtains non-exclusive access to the leading technology on the market for gene editing.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Alongside Evotec’s comprehensive stem cell capabilities, the ability to offer CRISPR-Cas9 research tools emphasises the Company’s continuing approach to establishing cutting-edge technologies for the benefit of our partners and growing R&D pipeline."
ABOUT THE CRISPR-CAS9 SYSTEM
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally-occurring bacterial immune system. Researchers have harnessed this system as a genome editing tool for mammalian cells. The CRISPR-Cas9 gene editing system allows researchers to target specific genes, to mutate these and achieve knock out or enhance the expression of these in living cells. Through application of the CRISPR-Cas9 technology, valuable insights into the functions of these genes in disease establishment and progression can be gained.